KC
KTTAW icon

Kepos Capital’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Kepos Capital’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4K Hold
334,600
– – 0.01% 136
2025
Q4 		$5K Hold
334,600
– – 0.03% 31
2025
Q3 		$6K Hold
334,600
– – 0.03% 36
2025
Q2 		$7K Hold
334,600
– – 0.01% 43
2025
Q1 		$6K Hold
334,600
– – 0.01% 49
2024
Q4 		$12K Hold
334,600
– – 0.01% 49
2024
Q3 		$12K Hold
334,600
– – 0.01% 208
2024
Q2 		$7K Hold
334,600
– – ﹤0.01% 211
2024
Q1 		$4K Hold
334,600
– – ﹤0.01% 241
2023
Q4 		$6K Hold
334,600
– – ﹤0.01% 198
2023
Q3 		$2K Hold
334,600
– – ﹤0.01% 266
2023
Q2 		$5K Buy
+334,600
New +$9.9K ﹤0.01% 328
2022
Q4 		$10K Hold
334,600
– – ﹤0.01% 363
2022
Q3 		$50K Hold
334,600
– – 0.01% 288
2022
Q2 		$22K Hold
334,600
– – ﹤0.01% 410
2022
Q1 		$57K Hold
334,600
– – ﹤0.01% 498
2021
Q4 		$124K Sell
334,600
-65,400
-16% -$32.2K 0.01% 475
2021
Q3 		$320K Buy
+400,000
New +$312K 0.02% 411

Other funds holding KTTAW

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Kepos Capital's KTTAW Position: Q1 2026 in Review

Kepos Capital held its Pasithea Therapeutics Warrants (KTTAW) position steady in Q1 2026 at 334,600 shares worth $4K. The position accounts for 0.01% of the portfolio, ranked #136.

Kepos Capital first reported a position in KTTAW in Q3 2021 and has held it in 18 quarters since. The position peaked at $320K in Q3 2021. 5 funds tracked by Wall St. Rank hold KTTAW as of Q1 2026.

  • Kepos Capital held 334,600 shares of Pasithea Therapeutics Warrants worth $4K as of Q1 2026.
  • Kepos Capital left its Pasithea Therapeutics Warrants share count unchanged in Q1 2026.
  • Pasithea Therapeutics Warrants made up 0.01% of Kepos Capital's portfolio in Q1 2026, its #136 holding.
  • Kepos Capital first reported a position in Pasithea Therapeutics Warrants in Q3 2021 and has held it in 18 quarters since.
  • Kepos Capital's Pasithea Therapeutics Warrants position peaked at $320K in Q3 2021.
  • 5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q1 2026.

Based on Kepos Capital's 13F filing for Q1 2026, filed 12 May 2026.